Healthcare Industry News: HSMN NewsFeed
News Release - June 2, 2017
Nexus Pharmaceuticals Receives FDA Approval for Sodium Nitroprusside InjectionVERNON HILLS, Ill., June 2, 2017 -- (Healthcare Sales & Marketing Network) -- Nexus Pharmaceuticals announced today the immediate availability in the United States of Sodium Nitroprusside Injection. Nexus Pharmaceuticals' Sodium Nitroprusside Injection is available as a single dose vial containing 50 mg per 2mL (25mg/mL) and is an AP Rated generic equivalent of Nitropress®.
Sodium Nitroprusside Injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure.
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals (www.nexuspharma.net) is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products. Through our high quality generic products, Nexus Pharmaceuticals is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. The company's headquarters is in Vernon Hills, Illinois.
Nitropress® is a registered trademark of Hospira Inc.
Source: Nexus Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.